Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Basaglar (insulin glargine) injection Right
  4. How are patients transitioned from another basal insulin to Basaglar® (insulin glargine)?
Search Basaglar (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Basaglar ® (insulin glargine) injection

100 units/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How are patients transitioned from another basal insulin to Basaglar® (insulin glargine)?

If transitioning from another basal insulin to Basaglar, the recommended initial Basaglar dose is based on the insulin therapy that is being discontinued.

US_cFAQ_BIV049_TRANSITION_TABLE
US_cFAQ_BIV049_TRANSITION_TABLE
en-US

Transitioning From Another Basal Insulin to Basaglar Therapy

If transitioning patients from another basal insulin to Basaglar® (insulin glargine) 100 units/mL therapy, the recommended initial dose of Basaglar is based on the insulin therapy that is being discontinued (Transitioning From Another Basal Insulin to Basaglar Therapy).1

Transitioning From Another Basal Insulin to Basaglar Therapy1

If transitioning from…

To…

Then the recommended initial dose of Basaglar…

Example

Lantus

Basaglar

is the same as the Lantus dose.

50 units of Lantus transitions to 50 units of Basaglar

Toujeo

Basaglar

is 80% of the Toujeo dose.

50 units of Toujeo transitions to 40 units of Basaglar

twice-daily NPH insulin

once-daily Basaglar

is 80% of the total daily NPH insulin dosage.

25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 40 units of Basaglar once daily

an intermediate- or long-acting insulin other than Lantus

Basaglar

may differ from the prior basal insulin dose.

…

Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL; Toujeo = Toujeo® (insulin glargine) 300 units/mL.

Enclosed Prescribing Information

BASAGLAR® (insulin glargine) injection, for subcutaneous use, Lilly

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: August 22, 2022

Additional related information:

  • How are patients transitioned from insulin degludec to Basaglar® (insulin glargine)?
  • How are patients transitioned from insulin detemir to Basaglar® (insulin glargine)?
  • How is Basaglar® (insulin glargine) therapy initiated and titrated?
Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Behringer Ingelheim partner logo and Lilly logo Behringer Ingelheim partner logo and Lilly logo